Abstract: Disclosed is an orthopedic implant suitable for arthroplasty procedures. The orthopedic implant includes a first plate, a second plate, an axial support between the first plate and the second plate and one or more torsional supports connecting the first plate and the second plate. The axial support may be, for example, one or more flexible struts, such as cables, or a ball and socket joint. The torsional supports connect the first and second plates and may be, for example, curved around the axial support. The torsional supports may be integrally formed with the first and second plates as a single unitary device, by, for example, a Laser Engineered Net Shape (LENS) process.

Abstract: Disclosed is an orthopedic implant suitable for arthroplasty procedures. The orthopedic implant includes a first plate, a second plate, an axial support between the first plate and the second plate and one or more torsional supports connecting the first plate and the second plate. The axial support may be, for example, one or more flexible struts, such as cables, or a ball and socket joint. The torsional supports connect the first and second plates and may be, for example, curved around the axial support. The torsional supports may be integrally formed with the first and second plates as a single unitary device, by, for example, a Laser Engineered Net Shape (LENS) process.

Abstract: This invention relates to methods of using O-substituted fumagillol derivatives or salts thereof preferably, O-(N-chloroacetylcarbamoyl) fumagillol, O-(N-chloroacetylcarbamoyl)dihydrofumagillol or O-(N-chloracetylcarbamoyl)-6'b-hydroxyfumagillol, which have angiogenesis inhibitory activity, in the treatment and prevention of various diseases caused or advanced by abnormally hyperactive angiogenesis, especially various inflammatory diseases (rheumatism, psoriasis, etc.), diabetic retinopathy and cancer and other angiogenesis-dependent tumors, especially Kaposi's sarcoma, breast cancer, colon cancer.

Abstract: O-substituted fumagillol derivatives and its salts have an angiogenesis inhibiting activity and are useful for prophylaxis and treatment of diseases induced by abnormally stimulated neovascularization.

Abstract: O-substituted fumagillol derivatives and its salts have an angiogenesis regressing activity are useful for treatment of diseases induced by abnormally stimulated neovascularization.

Abstract: Fumagillin and its salts have an angiogenesis inhibiting activity and are useful for prophylaxis and treatment of diseases induced by abnormally stimulated neovascularization. The invention also provides certain pharmaceutical compositions comprising fumagillin or its salt, and an agent which potentiates angiogenesis inhibition such as heparin and sulfated cyclodextrins such as beta-cyclodextrin tetradecasulfate.

Abstract: Angiostatic compounds are potentiated by collagen matrix metabolism modulators including:a) proline analogs which inhibit proline hydroxylation when substituted for proline in collagen;b) inhibitors of proline hydroxylase;c) inhibitors of collagen cross-linking; andd) all trans-retinoic acid.In methods and therapeutic compositions for inhibiting angiogenesis in a mammal, the collagen matrix modulator is administered with an angiostatic steroid or with heparin (including angiostatic heparin fragments of six or more sugar units, and synthetic fragments).